[{"id":"73c07069-865b-4afb-8b05-dfbb1671005a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04005690","created_at":"2021-01-29T07:19:28.601Z","updated_at":"2025-02-25T15:11:13.905Z","phase":"Phase 1","brief_title":"Targeted Pathway Inhibition in Patients With Pancreatic Cancer","source_id_and_acronym":"NCT04005690","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" UGT1A1 • CD4","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Cotellic (cobimetinib) • Imjudo (tremelimumab-actl) • onvansertib (PCM-075) • azenosertib (ZN-c3) • saruparib (AZD5305) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 08/01/2019","start_date":" 08/01/2019","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2025-02-13"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"9d379a3d-e6e5-4272-912a-3b641b499609","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616183","created_at":"2021-01-19T20:33:33.700Z","updated_at":"2024-07-02T16:35:00.055Z","phase":"Phase 1/2","brief_title":"LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer","source_id_and_acronym":"NCT04616183","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS • BRAF • MAP2K1","pipe":"","alterations":" ","tags":["KRAS • BRAF • MAP2K1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • Verzenio (abemaciclib) • temuterkib (LY3214996) • Datalai (cetuximab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 12/02/2020","start_date":" 12/02/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-30"},{"id":"cb3171df-fc1d-4edc-a68b-8e666a6750ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04391595","created_at":"2021-01-18T21:11:39.818Z","updated_at":"2024-07-02T16:35:12.669Z","phase":"Phase 1","brief_title":"LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients","source_id_and_acronym":"NCT04391595","lead_sponsor":"Nader Sanai","biomarkers":" CDKN2A • CDK4 • CDKN2B","pipe":" | ","alterations":" CDK4 amplification","tags":["CDKN2A • CDK4 • CDKN2B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/08/2020","start_date":" 07/08/2020","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-27"},{"id":"4e483bfe-5e97-41db-b857-047a1c9033b6","acronym":"","url":"https://clinicaltrials.gov/study/NCT02857270","created_at":"2021-01-18T14:01:31.198Z","updated_at":"2024-07-02T16:36:00.102Z","phase":"Phase 1","brief_title":"A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer","source_id_and_acronym":"NCT02857270","lead_sponsor":"Eli Lilly and Company","biomarkers":" BRAF • NRAS","pipe":" | ","alterations":" BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation","tags":["BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • NRAS mutation • BRAF V600 • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • gemcitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Braftovi (encorafenib) • temuterkib (LY3214996) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 210","initiation":"Initiation: 09/29/2016","start_date":" 09/29/2016","primary_txt":" Primary completion: 02/10/2021","primary_completion_date":" 02/10/2021","study_txt":" Completion: 10/24/2022","study_completion_date":" 10/24/2022","last_update_posted":"2022-11-22"},{"id":"0b0004ce-6bfe-4d8e-982a-5d46b487e30e","acronym":"SHERPA","url":"https://clinicaltrials.gov/study/NCT04916236","created_at":"2021-06-07T15:53:34.728Z","updated_at":"2024-07-02T16:36:09.403Z","phase":"Phase 1","brief_title":"Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers","source_id_and_acronym":"NCT04916236 - SHERPA","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" EGFR • KRAS • PIK3CA • MET • PTEN • HRAS","pipe":"","alterations":" ","tags":["EGFR • KRAS • PIK3CA • MET • PTEN • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vociprotafib (RMC-4630) • temuterkib (LY3214996)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 01/31/2024","primary_completion_date":" 01/31/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2022-06-03"},{"id":"1f11eaa1-672c-4dfd-9e60-d3744bf5457d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04043845","created_at":"2021-06-23T18:52:35.163Z","updated_at":"2024-07-02T16:36:50.440Z","phase":"Phase 1","brief_title":"ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies","source_id_and_acronym":"NCT04043845","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" PLCG2","pipe":"","alterations":" ","tags":["PLCG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imbruvica (ibrutinib) • temuterkib (LY3214996)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/03/2020","start_date":" 02/03/2020","primary_txt":" Primary completion: 02/03/2020","primary_completion_date":" 02/03/2020","study_txt":" Completion: 02/03/2020","study_completion_date":" 02/03/2020","last_update_posted":"2020-02-05"}]